To reduce the risk to workers developing and testing the COVID-19 vaccine, Pfizer-BioNTech and other companies have utilized a surrogate system, one of which was developed in the laboratory of Michael Whitt, PhD, a UTHSC virologist and UTRF innovator. Story written by Peggy Reisser, UTHSC Researchers at the University of Tennessee Health Science Center have (read more)
UTRF in the News
Discover 2020: UTRF Annual Report
UTRF is delighted to share Discover 2020, which celebrates our innovators and UTRF’s impact on innovation, new venture formation, and corporate engagement for the University of Tennessee. Download accessible PDF. View past annual reports.
UTRF Licensee Attralus Secures $25M in Investment
Professor Jonathan Wall and his team at the UT Graduate School of Medicine have spent more than two decades investigating systemic amyloidosis. Their work played an integral role in helping launch the biopharmaceutical company Attralus with technology licensed from UTRF. Today, Attralus announced that it has secured $25 million in investment financing to work on (read more)